- Home
- XERS vs MPB Comparison
XERS vs MPB Comparison
Compare XERS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | MPB |
|---|---|---|
| Founded | 2005 | 1868 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.0M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | XERS | MPB |
|---|---|---|
| Price | $6.28 | $33.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 1.2M | 135.9K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 2.66% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 2.55 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $30.95 |
| Revenue Next Year | $22.86 | $9.45 |
| P/E Ratio | ★ N/A | $13.03 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $25.83 |
| 52 Week High | $10.08 | $35.22 |
Technical Indicators
Market Signals| Indicator | XERS | MPB |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 51.14 |
| Support Level | $6.26 | $32.82 |
| Resistance Level | $6.41 | $34.88 |
| Average True Range (ATR) | 0.20 | 0.87 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 71.38 | 29.22 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.